Semaglutide is a long-acting GLP-1 receptor agonist, structurally modified to resist enzymatic degradation and allow for prolonged activity in the body. It mimics the action of endogenous glucagon-like peptide-1, a hormone that plays a key role in glucose-dependent insulin secretion, inhibition of glucagon release, and delayed gastric emptying.

Research has shown that semaglutide significantly improves glycemic control, reduces postprandial glucose spikes, and supports weight loss through appetite regulation and reduced food intake. It also has demonstrated cardiovascular benefits in some populations, making it a subject of interest in studies beyond glycemic management.

The 2 mg dose is typically used in long-term studies involving metabolic disorders, particularly type 2 diabetes and obesity, to assess its effects on insulin sensitivity, body weight, and overall endocrine function. Its extended half-life supports weekly dosing, making it a convenient candidate for chronic metabolic research protocols.